These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17055409)

  • 41. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How many drug targets are there?
    Overington JP; Al-Lazikani B; Hopkins AL
    Nat Rev Drug Discov; 2006 Dec; 5(12):993-6. PubMed ID: 17139284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 46. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How do pharmaceutical companies approach data from sexual health studies for regulatory agencies?
    Dilleen M; Haughie S
    Annu Rev Sex Res; 2005; 16():53-61. PubMed ID: 16913287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The loss of serendipity in psychopharmacology.
    Klein DF
    JAMA; 2008 Mar; 299(9):1063-5. PubMed ID: 18319418
    [No Abstract]   [Full Text] [Related]  

  • 53. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Re-examining our approach to the approval and use of new drugs.
    Lee SK
    CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
    [No Abstract]   [Full Text] [Related]  

  • 55. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
    Graul AI; Revel L; Tell M; Rosa E; Cruces E
    Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 57. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
    D'Este P; Tribó JA; García-Romero A
    Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sense and nonsense in post-authorization surveillance].
    de Mey C
    Med Klin (Munich); 2000 May; 95(1 Spec No):77-82. PubMed ID: 10851853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.